Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals is positioned for robust growth, particularly due to the expected increase in US peak sales for Dupixent, projected to reach approximately $21 billion by 2030, attributed to its expanding indications and physician overlap. The company's collaboration with Sanofi is set to enhance profitability, with a forecasted increase in Sanofi collaboration revenue by $1 billion in 2027, following the repayment of development costs in 3Q26, which will subsequently improve margins. Additionally, Regeneron's steady performance from core franchises, including Eylea, Dupixent, and Libtayo, coupled with successful allergy program trials, reinforces a diversified growth strategy that extends beyond existing products.

Regeneron Pharmaceuticals is experiencing a pivotal downturn, particularly as EYLEA sales decline due to the introduction of biosimilars and a slower adoption of EYLEA HD, which could negatively impact overall revenue. The company's pipeline is fraught with risks, as potential failures in development programs and heightened competition may hinder both future revenue growth and the expected performance of key products like Dupixent. Additionally, there is concern that failure to meet regulatory expectations, particularly for Libtayo in Non-Small Cell Lung Cancer, could create further challenges for Regeneron's long-term financial outlook.